Ajay Mansukhlal Patel, a promoter of Tatva Chintan Pharma Chem Limited, has filed a disclosure under SEBI Takeover Regulations announcing his proposed acquisition of 7,15,345 equity shares in the company. The transaction is scheduled to take place on or after February 6, 2026, through an inter-se off-market transfer of shares.

Transaction Details

The proposed acquisition involves the transfer of shares from Ajay Mansukhlal Patel (HUF) to Mr. Ajay Mansukhlal Patel as part of the dissolution and full partition of the Hindu Undivided Family (HUF). The transaction represents 3.06% of the company's total share capital and involves no monetary consideration.

Regulatory Compliance

The transaction falls under Regulation 10(1)(a)(ii) of the SEBI Takeover Regulations, which provides exemption from making an open offer. The acquirer has declared compliance with all applicable disclosure requirements under Chapter V of the SEBI Takeover Regulations and confirmed that all conditions specified under Regulation 10(1)(a) have been duly met.

Shareholding Impact

The proposed transaction will significantly alter the shareholding pattern of the promoter group. Ajay Mansukhlal Patel's individual holding will increase from 40,00,000 shares (17.10%) to 47,15,345 shares (20.16%). The overall promoter group shareholding, including Persons Acting in Concert (PACs), will rise from 49,00,000 shares (20.95%) to 56,15,345 shares (24.01%).

Rationale and Background

The proposed acquisition is being undertaken as part of a family arrangement for succession planning and rationalization of family assets and business holdings. The dissolution and partition of the HUF represents a strategic move to streamline ownership structures within the promoter group. Since the transaction involves distribution of assets upon HUF dissolution, no market price considerations apply, and the transfer is exempt from volume-weighted average price calculations typically required under SEBI regulations.

The disclosure was submitted to BSE Limited (Scrip Code: 543321), National Stock Exchange of India Limited (Symbol: TATVA), and the company's compliance officer on January 29, 2026, ensuring full regulatory transparency and adherence to prescribed timelines.

Tatva chintan pharma Chem has outlined ambitious revenue projections for its new product portfolio, indicating strong growth prospects in the specialty chemicals sector. The company shared forward-looking guidance during a recent conference call, providing insights into its strategic expansion plans.

Revenue Guidance for New Product Portfolio

The company has projected that new agro and pharma intermediates will contribute substantial revenue by calendar year 2027. The following table outlines the expected contribution:

Strategic Focus Areas

The guidance highlights Tatva Chintan Pharma Chem's strategic emphasis on expanding its product portfolio across two key segments:

• Agricultural Intermediates: Development of new chemical intermediates for agricultural applications
• Pharmaceutical Intermediates: Expansion in pharma intermediate manufacturing capabilities

Growth Trajectory

The projected revenue range of ₹200.00 crores to ₹250.00 crores from new intermediates represents a significant growth opportunity for the company. This guidance was communicated during a conference call, demonstrating management's confidence in the company's ability to develop and commercialize new products in the specialty chemicals space.

The timeline extends to calendar year 2027, providing a clear roadmap for the company's medium-term growth strategy. The focus on both agro and pharma intermediates reflects the company's diversified approach to capturing opportunities across multiple end-user industries.